Pharmacodynamic activity trial of JNJ-67484703 in rheumatoid arthritis, ulcerative colitis and Sjögren's syndrome (PARIS): a phase II proof of biology trial
Latest Information Update: 03 Apr 2024
At a glance
- Drugs JNJ-67484703 (Primary)
- Indications Rheumatoid arthritis; Sjogren's syndrome; Ulcerative colitis
- Focus Pharmacodynamics
- Acronyms PARIS
Most Recent Events
- 27 Mar 2024 Status changed from active, no longer recruiting to completed.
- 27 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 27 Mar 2023 The recruitment end date has been changed from 31/12/2022 to 15/06/2023.